Cencora, Inc. (NYSE:COR) Given Average Rating of “Moderate Buy” by Brokerages

Cencora, Inc. (NYSE:COR) has earned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $277.90.

COR has been the subject of a number of recent research reports. Wells Fargo & Company raised their target price on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th. Barclays boosted their target price on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. increased their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. UBS Group lifted their price target on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, Robert W. Baird upped their price objective on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th.

Insider Activity

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares in the company, valued at approximately $74,283,064.32. This trade represents a 6.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 73,187 shares of company stock valued at $17,790,912 in the last quarter. Insiders own 10.80% of the company’s stock.

Institutional Trading of Cencora

Several hedge funds have recently added to or reduced their stakes in COR. Czech National Bank increased its holdings in shares of Cencora by 12.6% in the 3rd quarter. Czech National Bank now owns 35,536 shares of the company’s stock valued at $7,998,000 after acquiring an additional 3,990 shares during the last quarter. Dynamic Advisor Solutions LLC increased its stake in Cencora by 15.2% in the third quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company’s stock valued at $262,000 after purchasing an additional 154 shares during the last quarter. LVW Advisors LLC raised its holdings in Cencora by 14.2% during the third quarter. LVW Advisors LLC now owns 3,666 shares of the company’s stock worth $825,000 after purchasing an additional 456 shares in the last quarter. Iowa State Bank purchased a new stake in shares of Cencora during the 3rd quarter worth approximately $1,390,000. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of Cencora by 33.7% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 27,375 shares of the company’s stock worth $6,160,000 after buying an additional 6,900 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

COR opened at $243.55 on Friday. The firm has a market cap of $47.07 billion, a P/E ratio of 34.64, a PEG ratio of 1.49 and a beta of 0.49. Cencora has a 1-year low of $214.77 and a 1-year high of $262.26. The company has a 50 day simple moving average of $238.70 and a two-hundred day simple moving average of $237.21. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.53.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities analysts forecast that Cencora will post 15.36 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date is Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.